Costunolide ameliorates autoimmune uveitis by targeting USP15 to suppress TNF-α-induced retinal endothelial inflammation
Proceedings of the National Academy of Sciences · 14.07.2026 · 123 (28)
DOI: 10.1073/pnas.2533845123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 07.07.2026. Verfasst von Yu Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Medical Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatmen…. Hauptthemen laut MEDLINE: Uveitis, Tumor Necrosis Factor-alpha, Autoimmune Diseases, Sesquiterpenes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation Key Program, Chongqing Outstanding Scientists Project, Chongqing Chief Medical Scientist Project.
Abstract (Originalsprache)
Autoimmune uveitis is a sight-threatening inflammatory disease, with the majority of entities driven by leukocyte infiltration into the retina. A critical early step in this process is the activation of retinal vascular endothelial cells (ECs), which up-regulate adhesion molecules that mediate T cell adhesion and subsequent extravasation. Here, we identify the small terpenoid compound costunolide (COS) as a potent suppressor of retinal endothelial inflammation and disease progression in experimental autoimmune uveitis (EAU). Quantitative proteomics of primary human retinal endothelial cells stimulated with TNF-α defined a proinflammatory endothelial signature and revealed induction of adhesion molecules. Screening of a focused library of 337 terpenoids uncovered COS as a top hit that markedly attenuated TNF-α-induced endothelial activation. In vivo, COS treatment significantly reduced clinical and histopathologic EAU scores, accompanied with reduced endothelial adhesion molecule expression and decreased T cell infiltration. Mechanistically, COS directly targeted deubiquitinase USP15, inhibiting USP15-dependent deubiquitination of TRAF1 and TNF signaling in retinal ECs. These findings establish COS as a candidate therapeutic agent for autoimmune uveitis and reveal a TNF-α–USP15–TRAF1 axis in retinal endothelium that can be pharmacologically exploited to limit pathogenic leukocyte trafficking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ophthalmology Medical Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Branch (Municipality Divis…
- Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.
Förderung
- National Natural Science Foundation Key Program
- Chongqing Outstanding Scientists Project
- Chongqing Chief Medical Scientist Project
- Chongqing Science and Technology Bureau Mountaineering Project
- Science and Technology Cooperation Project of the First Affiliated Hospital of Zhengzhou University (institution) 2025Hx39 (award-id) Peizeng Yang (principal-a…
Zitieren
APA
Gao, Y., Li, X., Dai, L., Luo, X., Su, G., Shi, K., Chen, L., & Yang, P. (2026). Costunolide ameliorates autoimmune uveitis by targeting USP15 to suppress TNF-α-induced retinal endothelial inflammation. Proceedings of the National Academy of Sciences, 123(28). https://doi.org/10.1073/pnas.2533845123
Vancouver
Gao Y, Li X, Dai L, Luo X, Su G, Shi K, et al. Costunolide ameliorates autoimmune uveitis by targeting USP15 to suppress TNF-α-induced retinal endothelial inflammation. Proceedings of the National Academy of Sciences. 2026;123(28). doi:10.1073/pnas.2533845123
BibTeX
@article{Gao2026,
author = {Gao, Yu and Li, Xingran and Dai, Lingyu and Luo, Xiang and Su, Guannan and Shi, Kai and Chen, Ling and Yang, Peizeng},
title = {Costunolide ameliorates autoimmune uveitis by targeting USP15 to suppress TNF-α-induced retinal endothelial inflammation},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {28},
doi = {10.1073/pnas.2533845123}
}
EUVIMED